Cost-effectiveness of World Health Organization 2010 Guidelines for Prevention of Mother-to-child HIV Transmission in Zimbabwe

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2012 Dec 4

PMID 23204035

Citations 28

Authors

Andrea L Ciaranello

Freddy Perez

Barbara Engelsmann

Rochelle P Walensky

Angela Mushavi

Asinath Rusibamayila

Jo Keatinge

Ji-Eun Park

Matthews Maruva

Rodrigo Cerda

Robin Wood

Francois Dabis

Kenneth A Freedberg

Affiliations

Soon will be listed here.

Abstract

Background: In 2010, the World Health Organization (WHO) released revised guidelines for prevention of mother-to-child human immunodeficiency virus (HIV) transmission (PMTCT). We projected clinical impacts, costs, and cost-effectiveness of WHO-recommended PMTCT strategies in Zimbabwe.

Methods: We used Zimbabwean data in a validated computer model to simulate a cohort of pregnant, HIV-infected women (mean age, 24 years; mean CD4 count, 451 cells/µL; subsequent 18 months of breastfeeding). We simulated guideline-concordant care for 4 PMTCT regimens: single-dose nevirapine (sdNVP); WHO-recommended Option A, WHO-recommended Option B, and Option B+ (lifelong maternal 3-drug antiretroviral therapy regardless of CD4). Outcomes included maternal and infant life expectancy (LE) and lifetime healthcare costs (2008 US dollars [USD]). Incremental cost-effectiveness ratios (ICERs, in USD per year of life saved [YLS]) were calculated from combined (maternal + infant) discounted costs and LE.

Results: Replacing sdNVP with Option A increased combined maternal and infant LE from 36.97 to 37.89 years and would reduce lifetime costs from $5760 to $5710 per mother-infant pair. Compared with Option A, Option B further improved LE (38.32 years), and saved money within 4 years after delivery ($5630 per mother-infant pair). Option B+ (LE, 39.04 years; lifetime cost, $6620 per mother-infant pair) improved maternal and infant health, with an ICER of $1370 per YLS compared with Option B.

Conclusions: Replacing sdNVP with Option A or Option B will improve maternal and infant outcomes and save money; Option B increases health benefits and decreases costs compared with Option A. Option B+ further improves maternal outcomes, with an ICER (compared with Option B) similar to many current HIV-related healthcare interventions.

Citing Articles

Modelling the potential clinical and economic impact of universal antenatal hepatitis C (HCV) screening and providing treatment for pregnant women with HCV and their infants in Egypt: a cost-effectiveness study.

Hachicha-Maalej N, Lepers C, Collins I, Mostafa A, Ades A, Judd A BMJ Public Health. 2025; 2(1):e000517.

PMID: 40018136 PMC: 11812807. DOI: 10.1136/bmjph-2023-000517.

The Cost of Maternal Complications and Its Associated Factors Among Mothers Attending Public Hospitals in Harari Region and Dire Dawa City Administration, Eastern Ethiopia: An Institution-Based Cross-Sectional Study.

Shawel S, Hawulte Ayele B, Dessie Y, Tura A, Dinsa G, Tekola A Clinicoecon Outcomes Res. 2023; 15:645-658.

PMID: 37701860 PMC: 10494998. DOI: 10.2147/CEOR.S416562.

Costs and Cost Drivers of Providing Option B+ Services to Mother-Baby Pairs for PMTCT of HIV in Health Centre IV Facilities in Jinja District, Uganda.

Mukose A, Kebede S, Muhumuza C, Makumbi F, Komakech H, Bayiga E Biomed Res Int. 2020; 2020:2875864.

PMID: 32550228 PMC: 7256705. DOI: 10.1155/2020/2875864.

Prevention of mother-to-child transmission (PMTCT) of HIV: a review of the achievements and challenges in Burkina-Faso.

Ghoma Linguissi L, Sagna T, Soubeiga S, Gwom L, Nkenfou C, Obiri-Yeboah D HIV AIDS (Auckl). 2019; 11:165-177.

PMID: 31440104 PMC: 6664853. DOI: 10.2147/HIV.S204661.

Cost-effectiveness of option B+ in prevention of mother-to-child transmission of HIV in Yunnan Province, China.

Wang X, Guo G, Zheng J, Lu L BMC Infect Dis. 2019; 19(1):517.

PMID: 31185927 PMC: 6560771. DOI: 10.1186/s12879-019-3976-5.

References

Kumwenda J, Matchere F, Mataya R, Chen S, Mipando L, Li Q . Coverage of highly active antiretroviral therapy among postpartum women in Malawi. Int J STD AIDS. 2011; 22(7):368-72. DOI: 10.1258/ijsa.2011.010359. View

Coutsoudis A, Pillay K, Kuhn L, Spooner E, Tsai W, Coovadia H . Method of feeding and transmission of HIV-1 from mothers to children by 15 months of age: prospective cohort study from Durban, South Africa. AIDS. 2001; 15(3):379-87. DOI: 10.1097/00002030-200102160-00011. View

Chasela C, Hudgens M, Jamieson D, Kayira D, Hosseinipour M, Kourtis A . Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med. 2010; 362(24):2271-81. PMC: 3440865. DOI: 10.1056/NEJMoa0911486. View

Kuhn L, Aldrovandi G, Sinkala M, Kankasa C, Mwiya M, Thea D . Potential impact of new WHO criteria for antiretroviral treatment for prevention of mother-to- child HIV transmission. AIDS. 2010; 24(9):1374-7. PMC: 2946203. View

El-Sadr W, Lundgren J, Neaton J, Gordin F, Abrams D, Arduino R . CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006; 355(22):2283-96. DOI: 10.1056/NEJMoa062360. View

Ciaranello A, Perez F, Maruva M, Chu J, Engelsmann B, Keatinge J . WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothers. PLoS One. 2011; 6(6):e20224. PMC: 3107213. DOI: 10.1371/journal.pone.0020224. View

Chigwedere P, Seage G, Lee T, Essex M . Efficacy of antiretroviral drugs in reducing mother-to-child transmission of HIV in Africa: a meta-analysis of published clinical trials. AIDS Res Hum Retroviruses. 2008; 24(6):827-37. DOI: 10.1089/aid.2007.0291. View

Kilewo C, Karlsson K, Ngarina M, Massawe A, Lyamuya E, Swai A . Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study. J Acquir Immune Defic Syndr. 2009; 52(3):406-16. DOI: 10.1097/QAI.0b013e3181b323ff. View

Carter R, Dugan K, El-Sadr W, Myer L, Otieno J, Pungpapong N . CD4+ cell count testing more effective than HIV disease clinical staging in identifying pregnant and postpartum women eligible for antiretroviral therapy in resource-limited settings. J Acquir Immune Defic Syndr. 2010; 55(3):404-10. DOI: 10.1097/QAI.0b013e3181e73f4b. View

10.

Dabis F, Bequet L, Ekouevi D, Viho I, Rouet F, Horo A . Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS. 2005; 19(3):309-18. PMC: 2474891. View

11.

Crampin A, Floyd S, Glynn J, Madise N, Nyondo A, Khondowe M . The long-term impact of HIV and orphanhood on the mortality and physical well-being of children in rural Malawi. AIDS. 2003; 17(3):389-97. DOI: 10.1097/00002030-200302140-00013. View

12.

Connor E, Sperling R, Gelber R, Kiselev P, Scott G, OSullivan M . Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994; 331(18):1173-80. DOI: 10.1056/NEJM199411033311801. View

13.

Toro P, Katyal M, Carter R, Myer L, El-Sadr W, Nash D . Initiation of antiretroviral therapy among pregnant women in resource-limited countries: CD4+ cell count response and program retention. AIDS. 2009; 24(4):515-24. DOI: 10.1097/QAD.0b013e3283350ecd. View

14.

Kaplan R, Orrell C, Zwane E, Bekker L, Wood R . Loss to follow-up and mortality among pregnant women referred to a community clinic for antiretroviral treatment. AIDS. 2008; 22(13):1679-81. PMC: 2741732. DOI: 10.1097/QAD.0b013e32830ebcee. View

15.

Zeh C, Weidle P, Nafisa L, Lwamba H, Okonji J, Anyango E . HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med. 2011; 8(3):e1000430. PMC: 3066134. DOI: 10.1371/journal.pmed.1000430. View

16.

Tonwe-Gold B, Ekouevi D, Viho I, Amani-Bosse C, Toure S, Coffie P . Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. PLoS Med. 2007; 4(8):e257. PMC: 1949842. DOI: 10.1371/journal.pmed.0040257. View

17.

Holmes C, Wood R, Badri M, Zilber S, Wang B, Maartens G . CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr. 2006; 42(4):464-9. DOI: 10.1097/01.qai.0000225729.79610.b7. View

18.

Walensky R, Wood R, Ciaranello A, Paltiel A, Lorenzana S, Anglaret X . Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis. PLoS Med. 2011; 7(12):e1000382. PMC: 3014084. DOI: 10.1371/journal.pmed.1000382. View

19.

Orlando S, Marazzi M, Mancinelli S, Liotta G, Ceffa S, Giglio P . Cost-effectiveness of using HAART in prevention of mother-to-child transmission in the DREAM-Project Malawi. J Acquir Immune Defic Syndr. 2011; 55(5):631-4. DOI: 10.1097/QAI.0b013e3181f9f9f5. View

20.

Palombi L, Marazzi M, Voetberg A, Magid N . Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV. AIDS. 2007; 21 Suppl 4:S65-71. DOI: 10.1097/01.aids.0000279708.09180.f5. View